Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M P Vierboom

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
European Journal of Immunology|June 1, 1993
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytesH W Nijman, J G Houbiers, M P Vierboom, et al.
European Journal of Immunology|September 1, 1993
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cellsM C Feltkamp, H L Smits, M P Vierboom, et al.
The Journal of Experimental Medicine|July 1, 1995
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cellsH W Nijman, M J Kleijmeer, M A Ossevoort, et al.
The Journal of Experimental Medicine|August 29, 1997
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, H W Nijman, R Offringa, et al.
Circulation Research|April 28, 2001
Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic miceB J van Vlijmen, G Gerritsen, A L Franken, et al.
Cancer Research|March 4, 1998
Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cellsM L De Bruijn, D H Schuurhuis, M P Vierboom, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
European Journal of Immunology|June 1, 1993
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytesH W Nijman, J G Houbiers, M P Vierboom, et al.
European Journal of Immunology|September 1, 1993
Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cellsM C Feltkamp, H L Smits, M P Vierboom, et al.
The Journal of Experimental Medicine|July 1, 1995
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cellsH W Nijman, M J Kleijmeer, M A Ossevoort, et al.
The Journal of Experimental Medicine|August 29, 1997
Tumor eradication by wild-type p53-specific cytotoxic T lymphocytesM P Vierboom, H W Nijman, R Offringa, et al.
Circulation Research|April 28, 2001
Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic miceB J van Vlijmen, G Gerritsen, A L Franken, et al.
Cancer Research|March 4, 1998
Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cellsM L De Bruijn, D H Schuurhuis, M P Vierboom, et al.
Pageof 2